Definitive Contract 75N93021C00030
Award Date
7/1/21
Potential Completion Date
6/30/24
Potential Value
$300K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Zymeron Corporation
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Research Triangle Park, NC 27709, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
6
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed
Similar Awards
The Department of Health and Human Services' National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $1,272,000.00 Firm Fixed Price, Definitive Contract to Zymeron Corporation, a minority-owned, for-profit biotechnology company. The contract is for the development of "Rapid Point of Care Tests to Simultaneously Quantify Anti-TB Drugs in Blood" under the Small Business Innovation Research (SBIR) Program Phase II. This research aligns with the...
This is a $599,061 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) within the Department of Health and Human Services (HHS). The purpose is to develop imprinted polymer resins for purifying HIV envelope vaccine candidates. The prime contractor is Zymeron Corporation, a minority-owned small business biotechnology company located in Research Triangle Park,...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a Firm Fixed Price Small Business Innovation Research (SBIR) Phase I contract to Zymeron Corporation, a minority-owned biotechnology company, to develop rapid point-of-care tests to simultaneously quantify anti-tuberculosis drugs in blood. The $299,920 contract, awarded on August 26, 2019, supports research and development to advance innovative diagnostics and...
The Zymeron Corporation was awarded a $299,998 firm fixed price Small Business Innovation Research Program Phase I contract from the National Institutes of Health's National Institute of Allergy and Infectious Diseases. The contract is for the research and development of a rapid point-of-care diagnostic test for histoplasmosis. This award falls under the larger SBIR solicitation issued by NIH and CDC seeking proposals in areas including cancer immunotherapy manufacturing, opioid withdrawal...
This is a $1,500,000.00 Firm Fixed Price contract awarded by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases to Zymeron Corporation, a minority-owned small business, to complete Phase II tasks for a Small Business Innovation Research (SBIR) program topic. The contract supports Zymeron's research and development of technologies focused on areas like protein degradation, antibacterials, antivirals, and drug delivery...
This contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Zymeron Corporation, a Minority Owned small business, under the Small Business Innovation Research (SBIR) Program. The objective is to develop a new chemical entity drug for proteolytic degradation of HIV Gag proteins. The contract is a Firm Fixed Price Definitive Contract with a potential value of $299,794.00 and a...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Darwin Biosciences, Inc., a minority-owned, woman-owned small business based in Broomfield, Colorado. The $299,408 firm-fixed-price contract is for the development of rapid diagnostic assays to aid in the self-monitoring of acute or rebound HIV-1 infection. The contract has an ultimate completion date of April 14, 2025. As an SBIR Phase I award,...
This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Virodx LLC, a minority-owned, woman-owned small business. The contract is for the development of a "METHOD FOR THE DETECTION OF MINORITY POPULATIONS OF DRUG RESISTANT HIV" and has a firm fixed price of $112,496.00 with a completion date of June 29, 2017. As this is an SBIR Phase I contract, the focus is on research...
This federal contract was awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Cell Microsystems Inc., a small business manufacturer of tools for cell research. The $283,407.00 contract is for the development of an HIV latent reservoir assay using a microwell array consumable under the Small Business Innovation Research (SBIR) program. This research supports efforts to improve assays for...
This is a $299,976.31 Firm Fixed Price definitive contract awarded by the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health (NIH), to Guild Associates Inc. (doing business as Guild Biosciences), a small business manufacturer. The contract is for the development of point-of-care HIV viral load and drug adherence assays under the NIH's Small Business Innovation Research (SBIR) program. This work was solicited under SBIR Topic 001 of the anticipated PHS-2024-1...